Gilead Sciences Inc (GILD)-Financial and Strategic SWOT Analysis Review
April 2017
62
About the Report
About the Report
Gilead Sciences Inc (GILD)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
Business description-A detailed description of the company's operations and business divisions.
Corporate strategy-Analyst's summarization of the company's business strategy.
SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.
Company history-Progression of key events associated with the company.
Major products and services-A list of major products, services and brands of the company.
Key competitors-A list of key competitors to the company.
Key employees-A list of the key executives of the company.
Executive biographies-A brief summary of the executives' employment history.
Key operational heads-A list of personnel heading key departments/functions.
Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.
Key manufacturing facilities-A list of key manufacturing facilities of the company.
Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Gilead Sciences Inc (Gilead) is a research-based biopharmaceutical company. It focuses on the discovery, development and commercialization of innovative medicines for diseases with unmet medical need. The company offers products in various therapeutic areas including cardiovascular, respiratory, inflammation, liver diseases, cancer and HIV/AIDS. Gilead operates through more than 40 marketing subsidiaries in the in Europe, North America, South America, Asia-Pacific, the Middle East, Africa and Australia. The company enters into partnerships with organizations in science, academia and business to develop innovative medicines. It continues to add to its existing portfolio of products through internal discovery and clinical development programs; and through a product acquisition and in-licensing strategy. Gilead is headquartered in Foster City, California, the US.
Gilead Sciences Inc Key Recent Developments
Apr 20,2017: Gilead to Present Clinical and Preclinical Data on Nonalcoholic Steatohepatitis at The International Liver Congress 2017
Feb 07,2017: Gilead Sciences Announces Fourth Quarter and Full Year 2016 Financial Results
Jan 10,2017: Gilead Awards More Than $22 Million in Grants to Support HIV Cure Research
Jan 09,2017: Mercy Philadelphia Hospital Receives FOCUS Award from Gilead Sciences
Jan 03,2017: Alessandro Riva, MD, to Join Gilead as Senior Vice President, Hematology and Oncology Therapeutic Area Head
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Products
Companies
Wave 80 Biosciences Inc United Therapeutics Corp Quanta BioDesign Ltd Ocera Therapeutics Inc Merck & Co Inc Janssen Therapeutics Islet Sciences Inc Intercept Pharmaceuticals Inc hVIVO Plc Enzon Pharmaceuticals Inc Celgene Corp Boehringer Ingelheim GmbH BioVentures Inc Actelion Pharmaceuticals US Inc Abbott Laboratories
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1-About the Company 6
Gilead Sciences Inc-Key Facts 6
Gilead Sciences Inc-Key Employees 7
Gilead Sciences Inc-Key Employee Biographies 9
Gilead Sciences Inc-Major Products and Services 11
Gilead Sciences Inc-Pharmaceutical Pipeline Products Data 13
Gilead Sciences Inc, Pipeline Products by Therapy Area 13
Gilead Sciences Inc, Pipeline Products by Development Phase 14
Gilead Sciences Inc-History 15
Gilead Sciences Inc-Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Joint Venture 25
Section 2-Company Analysis 26
Gilead Sciences Inc-Business Description 26
Gilead Sciences Inc-Corporate Strategy 28
Gilead Sciences Inc-SWOT Analysis 29
SWOT Analysis-Overview 29
Gilead Sciences Inc-Strengths 29
Gilead Sciences Inc-Weaknesses 30
Gilead Sciences Inc-Opportunities 31
Gilead Sciences Inc-Threats 33
Gilead Sciences Inc-Key Competitors 34
Section 3-Company Financial Ratios 35
Financial Ratios-Capital Market Ratios 35
Financial Ratios-Annual Ratios 36
Performance Chart 39
Financial Performance 39
Financial Ratios-Interim Ratios 40
Financial Ratios-Ratio Charts 41
Section 4-Company's Lifesciences Financial Deals and Alliances 42
Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 42
Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 43
Gilead Sciences Inc, Recent Deals Summary 44
Section 5-Company's Recent Developments 45
Feb 07, 2017: Gilead Sciences Announces Fourth Quarter and Full Year 2016 Financial Results 45
Jan 10, 2017: Gilead Awards More Than $22 Million in Grants to Support HIV Cure Research 47
Jan 09, 2017: Mercy Philadelphia Hospital Receives FOCUS Award from Gilead Sciences 48
Jan 03, 2017: Alessandro Riva, MD, to Join Gilead as Senior Vice President, Hematology and Oncology Therapeutic Area Head 49
Dec 16, 2016: Merck's subsidiary wins $2.5bn patent verdict against Gilead Sciences 50
Dec 16, 2016: Merck's subsidiary wins $2.5bn patent verdict against Gilead Sciences 51
Nov 16, 2016: Gilead Sciences Announces Promotion of James R. Meyers to Executive Vice President, Worldwide Commercial Operations 52
Nov 09, 2016: New Therapeutic Vaccine Approach Holds Promise for HIV Remission 53
Nov 01, 2016: Gilead Sciences Announces Third Quarter 2016 Financial Results 55
Oct 24, 2016: Gilead Sciences announces encouraging data from two Phase III HIV-1 studies 57
Section 6-Appendix 58
Methodology 58
Ratio Definitions 58
About GlobalData 62
Contact Us 62
Disclaimer 62
List of Figure
List of Figures
Gilead Sciences Inc, Pipeline Products by Therapy Area 13
Gilead Sciences Inc, Pipeline Products by Development Phase 14
Gilead Sciences Inc, Performance Chart (2012-2016) 39
Gilead Sciences Inc, Ratio Charts 41
Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 42
Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 43
List of Table
List of Tables
Gilead Sciences Inc, Key Facts 6
Gilead Sciences Inc, Key Employees 7
Gilead Sciences Inc, Key Employee Biographies 9
Gilead Sciences Inc, Major Products and Services 11
Gilead Sciences Inc, Number of Pipeline Products by Therapy Area 13
Gilead Sciences Inc, Number of Pipeline Products by Development Stage 14
Gilead Sciences Inc, History 15
Gilead Sciences Inc, Other Locations 21
Gilead Sciences Inc, Subsidiaries 21
Gilead Sciences Inc, Joint Venture 25
Gilead Sciences Inc, Key Competitors 34
Gilead Sciences Inc, Ratios based on current share price 35
Gilead Sciences Inc, Annual Ratios 36
Gilead Sciences Inc, Annual Ratios (Cont...1) 37
Gilead Sciences Inc, Annual Ratios (Cont...2) 38
Gilead Sciences Inc, Interim Ratios 40
Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 42
Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 43
Gilead Sciences Inc, Recent Deals Summary 44
Currency Codes 58
Capital Market Ratios 58
Equity Ratios 59
Profitability Ratios 59
Cost Ratios 60
Liquidity Ratios 60
Leverage Ratios 61
Efficiency Ratios 61
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.